Free Trial

Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60

Skye Bioscience logo with Medical background

Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) has received an average rating of "Buy" from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $16.60.

A number of equities research analysts have recently commented on SKYE shares. William Blair reaffirmed an "outperform" rating on shares of Skye Bioscience in a research note on Tuesday, May 20th. Craig Hallum reduced their price objective on shares of Skye Bioscience from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $15.00 price objective on shares of Skye Bioscience in a research note on Tuesday, June 24th.

Get Our Latest Stock Report on SKYE

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP lifted its position in shares of Skye Bioscience by 1.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,450,638 shares of the company's stock valued at $4,105,000 after acquiring an additional 16,004 shares during the period. Schonfeld Strategic Advisors LLC lifted its position in shares of Skye Bioscience by 48.3% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,422,741 shares of the company's stock valued at $4,026,000 after acquiring an additional 463,644 shares during the period. Braidwell LP acquired a new position in shares of Skye Bioscience during the 4th quarter valued at $2,337,000. Geode Capital Management LLC lifted its position in shares of Skye Bioscience by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 405,694 shares of the company's stock valued at $1,148,000 after acquiring an additional 19,901 shares during the period. Finally, Bridgeway Capital Management LLC lifted its position in shares of Skye Bioscience by 26.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 72,000 shares of the company's stock valued at $204,000 after acquiring an additional 15,000 shares during the period. Institutional investors and hedge funds own 21.09% of the company's stock.

Skye Bioscience Trading Up 9.7%

SKYE traded up $0.41 during trading on Thursday, reaching $4.58. 947,978 shares of the company's stock were exchanged, compared to its average volume of 498,649. Skye Bioscience has a one year low of $1.14 and a one year high of $7.47. The stock has a market capitalization of $141.73 million, a PE ratio of -5.58 and a beta of 1.95. The firm has a fifty day moving average price of $2.61 and a two-hundred day moving average price of $2.06.

Skye Bioscience (NASDAQ:SKYE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.03. Sell-side analysts expect that Skye Bioscience will post -1.04 earnings per share for the current year.

Skye Bioscience Company Profile

(Get Free Report

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.

Featured Stories

Analyst Recommendations for Skye Bioscience (NASDAQ:SKYE)

Should You Invest $1,000 in Skye Bioscience Right Now?

Before you consider Skye Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Skye Bioscience wasn't on the list.

While Skye Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines